Terms: = Breast cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Prognosis
1549 results:
1. MILIP Binding to tRNAs Promotes Protein Synthesis to Drive Triple-Negative breast cancer.
Zheng SM; Feng YC; Zhu Q; Li RQ; Yan QQ; Teng L; Yue YM; Han MM; Ye K; Zhang SN; Qi TF; Tang CX; Zhao XH; Zhang YY; Xu L; Xu R; Xing J; Baker M; Liu T; Thorne RF; Jin L; Preiss T; Zhang XD; Cang S; Gao JN
Cancer Res; 2024 May; 84(9):1460-1474. PubMed ID: 38593213
[TBL] [Abstract] [Full Text] [Related]
2. Tubulin alpha-1b chain was identified as a prognosis and immune biomarker in pan-cancer combing with experimental validation in breast cancer.
Wang Y; Li Y; Jing Y; Yang Y; Wang H; Ismtula D; Guo C
Sci Rep; 2024 Apr; 14(1):8201. PubMed ID: 38589634
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive bioinformatics analysis unveils THEMIS2 as a carcinogenic indicator related to immune infiltration and prognosis of thyroid cancer.
Liu JF; Zou B; Xiang C; Yan HC
Sci Rep; 2024 Apr; 14(1):8156. PubMed ID: 38589421
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
[TBL] [Abstract] [Full Text] [Related]
5. Comprehensive evaluation of the relationship between biomarker profiles and neoadjuvant chemotherapy outcomes for breast cancer patients.
Wang M; Wei Z; Kong J; Zhao H
Diagn Pathol; 2024 Mar; 19(1):53. PubMed ID: 38509525
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive genomic profiling to identify actionable alterations for breast cancer brain metastases in the Chinese population.
Lu Q; Wang N; Jiang K; Zhou H; Zhang P; Zhang J; Wang S; Sun P; Xu F
ESMO Open; 2024 Mar; 9(3):102389. PubMed ID: 38460250
[TBL] [Abstract] [Full Text] [Related]
7. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
Smoots SG; Schreiber AR; Jackson MM; Bagby SM; Dominguez ATA; Dus ED; Binns CA; MacBeth M; Whitty PA; Diamond JR; Pitts TM
Breast Cancer Res; 2024 Mar; 26(1):35. PubMed ID: 38429789
[TBL] [Abstract] [Full Text] [Related]
8. Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced breast cancer Receiving Palbociclib: Results From the TREnd Trial.
Migliaccio I; Romagnoli D; Galardi F; De Luca F; Biagioni C; Curigliano G; Criscitiello C; Minisini AM; Moretti E; Risi E; Guarducci C; Nardone A; Biganzoli L; Benelli M; Malorni L
JCO Precis Oncol; 2024 Feb; 8():e2300285. PubMed ID: 38427931
[TBL] [Abstract] [Full Text] [Related]
9. Identification of a Group of Therapeutic Targets and Prognostic Biomarker for Triple Negative breast cancer.
Li Y; Yang S; Qi L; Li Y; Wang X
Adv Ther; 2024 Apr; 41(4):1621-1636. PubMed ID: 38421558
[TBL] [Abstract] [Full Text] [Related]
10. Somatic mutations in a multigene panel and impact on prognosis based on tp53 status in Chinese HER2-positive patients undergoing neoadjuvant therapy: A single-institution retrospective cohort.
Xiong M; Wang X; Liu D; Xiu B; Zhang Q; Chi W; Goh CW; Zhang L; Chen M; Ren H; Shao ZM; Yang B; Wu J
Cancer Med; 2024 Jan; 13(2):e6955. PubMed ID: 38379328
[TBL] [Abstract] [Full Text] [Related]
11. tp53
Su Y; Zhao J; Fu H; Liu Z; Du P; Zheng J; Wu J; Zhang J
Biochem Pharmacol; 2024 Mar; 221():116047. PubMed ID: 38331350
[TBL] [Abstract] [Full Text] [Related]
12. Vasculogenic mimicry regulates immune infiltration and mutational status of the tumor microenvironment in breast cancer to influence tumor prognosis.
Zheng S; Guo G; Yang Z; Lu Y; Lu K; Fu W; Huang Q
Environ Toxicol; 2024 May; 39(5):2948-2960. PubMed ID: 38308456
[TBL] [Abstract] [Full Text] [Related]
13. Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy.
Yin G; Liu L; Yu T; Yu L; Feng M; Zhou C; Wang X; Teng G; Ma Z; Zhou W; Ye C; Zhang J; Ji C; Zhao L; Zhou P; Guo Y; Meng X; Fu Q; Zhang Q; Li L; Zhou F; Zheng C; Xiang Y; Guo M; Wang Y; Wang F; Huang S; Yu Z
Genome Med; 2024 Jan; 16(1):11. PubMed ID: 38217005
[TBL] [Abstract] [Full Text] [Related]
14. p53 expression correlates with low axillary tumor burden in breast cancer.
Nicolau P; Masó P; Argudo N; Jiménez M; Martínez AI; Vázquez I; Comerma L; Vernet-Tomás M
Breast Dis; 2023; 42(1):429-435. PubMed ID: 38143332
[TBL] [Abstract] [Full Text] [Related]
15. Construction of a risk stratification model integrating ctDNA to predict response and survival in neoadjuvant-treated breast cancer.
Liu Z; Yu B; Su M; Yuan C; Liu C; Wang X; Song X; Li C; Wang F; Ma J; Wu M; Chen D; Yu J; Yu Z
BMC Med; 2023 Dec; 21(1):493. PubMed ID: 38087296
[TBL] [Abstract] [Full Text] [Related]
16. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
[TBL] [Abstract] [Full Text] [Related]
17. Novel disulfidptosis-derived gene blueprint stratifying patients with breast cancer.
Tang X; Ping B; Liu Y; Zhou Y
Environ Toxicol; 2024 Mar; 39(3):1715-1728. PubMed ID: 38050844
[TBL] [Abstract] [Full Text] [Related]
18. Genetic and clinical landscape of ER + /PR- breast cancer in China.
Dai D; Wu H; Zhuang H; Chen R; Long C; Chen B
BMC Cancer; 2023 Dec; 23(1):1189. PubMed ID: 38049758
[TBL] [Abstract] [Full Text] [Related]
19. An emerging biomarker for the diagnosis and treatment of esophageal squamous cell carcinoma - Aurora A.
Zhou W; Guo S; Zhang J; Yan Y; Wu J; Liu X
Comput Biol Med; 2024 Jan; 168():107759. PubMed ID: 38043467
[TBL] [Abstract] [Full Text] [Related]
20. Elevated expression of TUBA1C in breast cancer predicts poor prognosis.
Zhao Y; Wang W; Li J; Du J; Xie Q; Wang M; Liu Z; Huo X; Zhao F; Ren D; Zhao J; Shen G
PLoS One; 2023; 18(11):e0263710. PubMed ID: 38032902
[TBL] [Abstract] [Full Text] [Related]
[Next]
